Close Menu

NEW YORK (GenomeWeb) – Curetis today reported a 41 percent year-over-year increase in its first quarter revenues, thanks largely to surging sales of its diagnostic test cartridges and instruments in Europe, the Middle East, and Asia (EMEA).

For the three-month period ended March 31, Curetis' revenues climbed to €490,000 ($577,490) from €347,000 a year earlier. Contributing to the growth was a 518 percent bounce in sales of the firm's Unyvero molecular diagnostic instrument and related cartridges in EMEA direct selling markets.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.